alertmeipp
9 minutes ago
ED-235 is probably more valuable to PFE than anyone else. Then, RSV and the patent lawsuit settlement could all bring significant value to Pfizer. As well, PFE is under pressure to replenish its drug pipeline, ENTA's intellectual property and immunology program could provide crucial support in this